Brief: Plus Therapeutics Announces FDA Agreement To Initiate ReSPECT-LM Dose Optimization Trial For REYOBIQ In Leptomeningeal Metastases
30/06/2025 12:32
June 30 (Reuters) - Plus Therapeutics Inc PSTV.O: PLUS THERAPEUTICS ANNOUNCES FDA AGREEMENT TO INITIATE RESPECT-LM DOSE OPTIMIZATION TRIAL FOR REYOBIQ™ IN LEPTOMENINGEAL METASTASES PLUS THERAPEUTICS INC - TRIAL TO EVALUATE SAFETY, PHARMACOKINETICS, AND EFFICACY ENDPOINTS PLUS THERAPEUTICS INC - TRIAL TO ENROLL UP TO 24 PATIENTS AT 44.1 MCI DOSE Source text: ID:nGNX2L2Dlq Further company coverage: PSTV.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cerenome
See all newsBrief: Cerenome Secures In-Network Agreement With Florida Blue For Cnside® Csf Tumor Cell Enumeration And Molecular Profile Tests
Plus Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Cerenome Secures In-Network Agreement With Health Care Service Corporation
Plus Therapeutics Inc expected to post a loss of 91 cents a share - Earnings Preview
Brief: Plus Therapeutics Secures Regional Coverage Agreement With Medical Mutual For CNSide Cerebrospinal Fluid Assay For Metastatic CNS Cancer